Deals: Page 2

  • Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca to invest $300M in US cell therapy plant

    The UK drugmaker is adding a facility in Rockville, Maryland, after a spate of dealmaking in the therapeutic field.

    By Kristin Jensen • Feb. 7, 2024
  • A Novartis logo is seen on the side of an office building.
    Image attribution tooltip
    Permission granted by Novartis
    Image attribution tooltip

    MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte

    The deals would hand Novartis a myelofibrosis drug with uncertain regulatory prospects and Incyte a marketed lymphoma medicine that hasn’t sold well.

    By • Feb. 6, 2024
  • Explore the Trendline➔
    Image attribution tooltip
    Brian Tucker / BioPharma Dive
    Image attribution tooltip
    Trendline

    Biotech dealmaking

    Acquisitions of biotech companies have picked up in recent quarters, suggesting depressed valuations may be facilitating deal conversations. Read this trendline for a look at the factors impacting M&A. 

    By BioPharma Dive staff
  • White flags bearing Novo Nordisk's logo are seen against a blue sky.
    Image attribution tooltip
    Courtesy of Novo Nordisk
    Image attribution tooltip
    Obesity drugs

    Novo Holdings to buy contract drugmaker Catalent for $16.5B

    In a related deal, Novo Holdings subsidiary Novo Nordisk will buy three major Catalent factories for $11 billion as it works to keep pace with demand for its obesity and diabetes medicines.

    By • Feb. 5, 2024
  • Image attribution tooltip
    Flickr; Joel Penner
    Image attribution tooltip

    Valneva sells regulatory ‘fast pass’ for $103M

    The company said it will invest the sale proceeds into testing of an experimental Lyme disease shot and of Ixchiq, its new chikungunya vaccine.

    By • Feb. 5, 2024
  • Photo of Takeda Pharmaceutical's global headquarters in Japan.
    Image attribution tooltip
    Courtesy of Takeda Pharmaceuticals
    Image attribution tooltip

    Takeda pays $300M to license Protagonist drug for blood disorder

    The agreement gives Protagonist an experienced partner in Takeda, which should help the former commercialize its polycythemia vera treatment.

    By Kristin Jensen • Feb. 1, 2024
  • A Roche logo is seen on the side of a building.
    Image attribution tooltip
    Courtesy of Roche
    Image attribution tooltip

    Roche shuffles early stage pipeline as it joins obesity rush

    Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.

    By • Feb. 1, 2024
  • People walk past the Nasdaq MarketSite on October 12, 2022 in New York City.
    Image attribution tooltip
    Michael M. Santiago via Getty Images
    Image attribution tooltip

    Avrobio’s road ends in reverse merger with Tim Springer-backed startup

    The gene therapy developer’s demise has given Tectonic Therapeutic, a GPCR-focused startup founded by the prolific biotech entrepreneur, an alternate path to the public markets.

    By Kristin Jensen • Jan. 31, 2024
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead deepens investment in Arcus and TIGIT drugs

    The companies said the deal shows their “continued conviction in the TIGIT pathway,” an area of research that so far has not lived up to expectations.

    By • Jan. 30, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    RayzeBio drew other pharma interest before Bristol Myers deal

    Two “global biopharmaceutical companies” made bids to buy the radiopharma specialist, but lost out to Bristol Myers, which negotiated aggressively to secure a $4.1 billion buyout.

    By • Jan. 25, 2024
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    hapabapa via Getty Images
    Image attribution tooltip

    Novo strikes another obesity drug deal

    The partnership with startup EraCal Therapeutics, a spinout of Harvard University and Zurich University, adds another prospect to Novo’s pipeline of weight loss drugs. 

    By Kristin Jensen • Jan. 24, 2024
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi to buy Inhibrx in deal worth up to $2.2B

    The acquisition will give Sanofi an experimental drug for alpha-1 antitrypsin deficiency, while the rest of Inhibrx's assets will be spun into a new company.

    By • Jan. 23, 2024
  • A prescription drug carton with information for the biosimilar medicine Cimerli is pictured against a white background.
    Image attribution tooltip
    Courtesy of Coherus Biosciences
    Image attribution tooltip

    Coherus sells Lucentis biosimilar to Sandoz for $170M

    The divestment, which includes sales and reimbursement staff, is part of Coherus’ plan to shift resources toward its R&D work in oncology.

    By • Jan. 22, 2024
  • A conceptual illustration of neural activity in a brain.
    Image attribution tooltip
    nopparit via Getty Images
    Image attribution tooltip

    Karuna, Cerevel might be just the start of psychiatry drug M&A

    New details of the proposed buyouts show there were multiple interested buyers, which, according to analysts, could set the stage for more dealmaking.

    By • Jan. 22, 2024
  • Image attribution tooltip
    Warren Little via Getty Images
    Image attribution tooltip

    GSK to buy asthma drug startup Aiolos for $1B

    Aiolos, which raised a Series A round three months ago, is developing an antibody that shares a target with Amgen and AstraZeneca’s Tezspire.

    By • Jan. 9, 2024
  • The Merck & Co. sign at the company's building in Summit, New Jersey.
    Image attribution tooltip
    Kena Betancur via Getty Images
    Image attribution tooltip

    Merck pays $680M for struggling cancer biotech Harpoon

    The acquisition will build out Merck’s pipeline of immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.

    By • Jan. 8, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J to acquire ADC drug developer Ambrx for $2B

    The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.

    By • Jan. 8, 2024
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers to acquire brain drug developer Karuna for $14B

    The deal would hand Bristol Myers, which is reprioritizing neuroscience research, an experimental treatment for schizophrenia that analysts think could become a blockbuster product.

    By , • Updated Dec. 22, 2023
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J bets bigger on MeiraGTx’s eye gene therapy

    Ahead of a Phase 3 readout that could come next year, the pharma is paying $130 million in upfront and near-term cash for rights to the retinitis pigmentosa treatment that it didn’t already own.

    By • Dec. 21, 2023
  • The Federal Trade Commission's building sign.
    Image attribution tooltip
    Gromit702 via Getty Images
    Image attribution tooltip

    FTC, DOJ finalize merger guidelines that could impede healthcare deals

    The new guidelines may give regulators more ammunition to go after vertical and cross-market M&A that has historically been more difficult to challenge.

    By Rebecca Pifer • Dec. 19, 2023
  • A concept illustration of malignant cells, colored purple and red
    Image attribution tooltip
    koto_feja via Getty Images
    Image attribution tooltip

    Point radiopharma drug results disappoint in prostate cancer study

    While the study met its goal, the drug’s benefit was less than analysts had predicted, an outcome that could hasten a planned takeover by Eli Lilly.

    By • Dec. 18, 2023
  • The Federal Trade Commission headquarters is pictured in Washington, D.C. The agency's proposed noncompete ban may face legal challenges on several grounds.
    Image attribution tooltip
    RiverNorthPhotography via Getty Images
    Image attribution tooltip

    FTC, in unusual move, leads Sanofi to terminate a drug research deal

    Just before clearing Pfizer’s buyout of Seagen, the regulator threatened to block Sanofi’s licensing deal with Maze Therapeutics, a challenge the biotech called ‘‘unprecedented.”

    By • Dec. 12, 2023
  • Corporate logos are seen outside on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    AstraZeneca to acquire vaccine maker Icosavax for up to $1.1B

    The deal signals the pharma company’s continuing interest in vaccine development and hands it a combination shot aimed at two respiratory viruses. 

    By • Dec. 12, 2023
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree

    The lucrative alliance, potentially worth more than $8 billion, continues a run of dealmaking for a class of cancer drugs that’s surged in popularity in recent years. 

    By • Dec. 12, 2023
  • A stylized stock chart is superimposed over a picture of U.S. dollars.
    Image attribution tooltip
    Maximusnd via Getty Images
    Image attribution tooltip

    Spyre Therapeutics raises $180 million to advance anti-inflammatory drugs

    The private placement funding will help Spyre develop its drug pipeline, which includes a TL1A-targeting therapy for inflammatory bowel disease.

    By • Dec. 8, 2023
  • Brain scans are seen in a stock image
    Image attribution tooltip
    sudok1 via Getty Images
    Image attribution tooltip

    AbbVie to buy Cerevel in $8.7B bet on brain drugs

    The deal hands AbbVie a portfolio of psychiatric medicines that originated within Pfizer, among them a closely watched schizophrenia treatment that’s in late-stage testing.

    By , • Updated Dec. 6, 2023